Identification of protective antigens for vaccination against systemic salmonellosis

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages 1-5

  Bumann, Dirk ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antigen expression; Human clinical trials; Immunodominance; Mouse model; Protective immunity; Salmonella enterica; Typhoid vaccines

Indexed keywords

ANTIGEN; SUBUNIT VACCINE; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; PROTEOMICS; SALMONELLA TYPHI; SALMONELLOSIS; TYPHOID FEVER; VACCINATION; VIRULENCE;

EID: 84923699059     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00381     Document Type: Article

References (50)

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 380:2095-128. doi:10.1016/S0140-6736(12)61728-0
2. Crump JA, Mintz ED.Global trends in typhoid and paratyphoid fever. Clin Infect Dis (2010) 50:241-6. doi:10.1086/649541
3. Maclennan CA, Levine MM. Invasive nontyphoidal Salmonella disease in Africa: current status. Expert Rev Anti Infect Ther (2013) 11:443-6. doi:10.1586/ eri.13.27
4. Jean SS, Hsueh PR.High burden of antimicrobial resistance inAsia. Int J Antimi-crob Agents (2011) 37:291-5. doi:10.1016/j.ijantimicag.2011.01.009
5. Martin LB. Vaccines for typhoid fever and other salmonelloses. Curr Opin Infect Dis (2012) 25:489-99. doi:10.1097/QCO.0b013e328356ffeb
6. Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L. Vaccines for preventing typhoid fever. Cochrane Database Syst Rev (2014) 1:CD001261. doi:10.1002/14651858.CD001261.pub3
7. Maclennan CA, Martin LB, Micoli F. Vaccines against invasive Salmonella dis-ease: current status and future directions. Hum Vaccin Immunother (2014) 10:33-48. doi:10.4161/hv.29054
8. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 33:530-41. doi:10.1016/j.immuni.2010.09.017
9. Nuccio SP, Baumler AJ. Comparative analysis of Salmonella genomes identifies a metabolic network for escalating growth in the infiamed gut. MBio (2014) 5:e929-914. doi:10.1128/mBio.00929-14
10. Barat S, Willer Y, Rizos K, Claudi B, Maze A, Schemmer AK, et al. Immunity to intracellular salmonella depends on surface-associated antigens. PLo S Pathog (2012) 8:e1002966. doi:10.1371/journal.ppat.1002966
11. Song J, Gao X, Galan JE. Structure and function of the Salmonella Typhi chimaeric A(2)B(5) typhoid toxin. Nature (2013) 499:350-4. doi:10.1038/ nature12377
12. Becker D, Selbach M, Rollenhagen C, Ballmaier M, Meyer TF, Mann M, et al. Robust Salmonella metabolism limits possibilities for new antimicrobials. Nature (2006) 440:303-7. doi:10.1038/nature04616
13. Steeb B, Claudi B, Burton NA, Tienz P, Schmidt A, Farhan H, et al. Paral-lel exploitation of diverse host nutrients enhances Salmonella virulence. PLo S Pathog (2013) 9:e1003301. doi:10.1371/journal.ppat.1003301
14. Kurtz JR, Petersen HE, Frederick DR, Morici LA, Mclachlan JB.Vaccination with a single CD4 T cell peptide epitope from a Salmonella type III-secreted effec-tor protein provides protection against lethal infection. Infect Immun (2014) 82:2424-33. doi:10.1128/IAI.00052-14
15. Rollenhagen C, Sorensen M, Rizos K, Hurvitz R, Bumann D. Antigen selec-tion based on expression levels during infection facilitates vaccine development for an intracellular pathogen. Proc Natl Acad Sci U S A (2004) 101:8739-44. doi:10.1073/pnas.0401283101
16. Rollenhagen C, Bumann D. Salmonella enterica highly expressed genes are dis-ease specific. Infect Immun (2006) 74:1649-60. doi:10.1128/IAI.74.3.1649-1660. 2006
17. Woodward WE. Volunteer studies of typhoid fever and vaccines. Trans R Soc Trop Med Hyg (1980) 74:553-6. doi:10.1016/0035-9203(80)90133-9
18. Levine MM, Tacket CO, Sztein MB. Host-Salmonella interaction: human trials. Microbes Infect (2001) 3:1271-9. doi:10.1016/S1286-4579(01)01487-3
19. Waddington CS, Darton TC, Jones C, Haworth K, Peters A, John T, et al. An out-patient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution. Clin Infect Dis (2014) 58:1230-40. doi:10.1093/cid/ciu078
20. Bumann D, Hueck C, Aebischer T, Meyer TF. Recombinant live Salmonella spp. for human vaccination against heterologous pathogens. FEMS Immunol Med Microbiol (2000) 27:357-64. doi:10.1111/j.1574-695X.2000.tb01450.x
21. Tacket CO, Levine MM. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.Clin Infect Dis (2007) 45(Suppl 1):S20-3. doi:10.1086/518135
22. Frey SE, Lottenbach KR, Hill H, Blevins TP, Yu Y, Zhang Y, et al. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vac-cine vectors producing Streptococcus pneumoniae surface protein antigen Psp A. Vaccine (2013) 31:4874-80. doi:10.1016/j.vaccine.2013.07.049
23. Lee SJ, Liang L, Juarez S, Nanton MR, Gondwe EN, Msefula CL, et al. Identi-fication of a common immune signature in murine and human systemic Sal-monellosis. Proc Natl Acad Sci U S A (2012) 109:4998-5003. doi:10.1073/pnas. 1111413109
24. Liang L, Juarez S, Nga TV, Dunstan S, Nakajima-Sasaki R, Davies DH, et al. Immune profiling with a Salmonella Typhi antigen microarray identifies new diagnostic biomarkers of human typhoid. Sci Rep (2013) 3:1043. doi:10.1038/ srep01043
25. Maybeno M, Redeker A, Welten SP, Peters B, Loughhead SM, Schoenberger SP, et al. Polyfunctional CD4(+) T cell responses to immunodominant epitopes cor-relate with disease activity of virulent Salmonella. PLo S One (2012) 7:e43481. doi:10.1371/journal.pone.0043481
26. Sheikh A, Khanam F, Sayeed MA, Rahman T, Pacek M, Hu Y, et al. Interferon-gamma and proliferation responses to Salmonella enterica serotype Typhi pro-teins in patients with S. Typhi Bacteremia in Dhaka, Bangladesh. PLo S Negl Trop Dis (2011) 5:e1193. doi:10.1371/journal.pntd.0001193
27. Reynolds CJ, Jones C, Blohmke CJ, Darton TC, Goudet A, Sergeant R, et al. The serodominant secreted effector protein of Salmonella, Sse B, is a strong CD4 anti-gen containing an immunodominant epitope presented by diverse HLA class II alleles. Immunology (2014):doi:10.1111/imm.12327
28. Cookson BT, Bevan MJ. Identification of a natural T cell epitope presented by Salmonella-infected macrophages and recognized by T cells from orally immu-nized mice. J Immunol (1997) 158:4310-9.
29. Lee SJ, Mclachlan JB, Kurtz JR, Fan D, Winter SE, Baumler AJ, et al. Tempo-ral expression of bacterial proteins instructs host CD4 T cell expansion and th17 development. PLo S Pathog (2012) 8:e1002499. doi:10.1371/journal.ppat. 1002499
30. Burton NA, Schurmann N, Casse O, Steeb AK, Claudi B, Zankl J, et al. Disparate impact of oxidative host defenses determines the fate of Salmo-nella during systemic infection in mice. Cell Host Microbe (2014) 15:72-83. doi:10.1016/j.chom.2013.12.006
31. Mc Sorley SJ, Cookson BT, Jenkins MK. Characterization of CD4+ T cell responses during natural infection with Salmonella Typhimurium. J Immunol (2000) 164:986-93. doi:10.4049/jimmunol.164.2.986
32. Gil-Cruz C, Bobat S, Marshall JL, Kingsley RA, Ross EA, Henderson IR, et al. The porin Omp D from nontyphoidal Salmonella is a key target for a protec-tive B1b cell antibody response. Proc Natl Acad Sci U S A (2009) 106:9803-8. doi:10.1073/pnas.0812431106
33. Yang Y, Wan C, Xu H, Aguilar ZP, Tan Q, Xu F, et al. Identification of an outer membrane protein of Salmonella enterica serovar Typhimurium as a potential vaccine candidate for Salmonellosis in mice. Microbes Infect (2013) 15:388-98. doi:10.1016/j.micinf.2013.02.005
34. Paramasivam N, Linke D. Club Sub-P: cluster-based subcellular localization pre-diction for Gram-negative bacteria and archaea. Front Microbiol (2011) 2:218. doi:10.3389/fmicb.2011.00218
35. Freeman TC Jr., Wimley WC. TMBB-DB: a transmembrane beta-barrel pro-teome database. Bioinformatics (2012) 28:2425-30. doi:10.1093/bioinformatics/ bts478
36. Diaz-Mejia JJ, Babu M, Emili A. Computational and experimental approaches to chart the Escherichia coli cell-envelope-associated proteome and interactome. FEMS Microbiol Rev (2009) 33:66-97. doi:10.1111/j.1574-6976.2008.00141.x
37. Chooneea D, Karlsson R, Encheva V, Arnold C, Appleton H, Shah H. Elucidation of the outer membrane proteome of Salmonella enterica serovar Typhimurium utilising a lipid-based protein immobilization technique. BMCMicrobiol (2010) 10:44. doi:10.1186/1471-2180-10-44
38. Brown RN, Sanford JA, Park JH, Deatherage BL, Champion BL, Smith RD, et al. A comprehensive subcellular proteomic survey of Salmonella grown under phagosome-mimicking versus standard laboratory conditions. Int J Proteomics (2012) 2012:123076. doi:10.1155/2012/123076
39. Sabarth N, Lamer S, Zimny-Arndt U, Jungblut PR, Meyer TF, Bumann D. Identi-fication of surface-exposed proteins of Helicobacter pylori by selective biotinyla-tion, affinity purification, and two-dimensional gel electrophoresis. J Biol Chem (2002) 277:27896-902. doi:10.1074/jbc.M204473200
40. Figueira R, Watson KG, Holden DW, Helaine S. Identification of Salmonella pathogenicity island-2 type III secretion system effectors involved in intra-macrophage replication of S. enterica serovar typhimurium: implications for rational vaccine design. MBio (2013) 4:e00065. doi:10.1128/mBio.00065-13
41. Dougan G, John V, Palmer S, Mastroeni P. Immunity to salmonellosis. Immunol Rev (2011) 240:196-210. doi:10.1111/j.1600-065X.2010.00999.x
42. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature (2014) 509:361-5. doi:10.1038/nature13160
43. Valdez Y, Ferreira RB, Finlay BB. Molecular mechanisms of Salmonella vir-ulence and host resistance. Curr Top Microbiol Immunol (2009) 337:93-127. doi:10.1007/978-3-642-01846-6_4
44. Nanton MR, Way SS, Shlomchik MJ, Mc Sorley SJ. Cutting edge: B cells are essential for protective immunity against Salmonella independent of antibody secretion. J Immunol (2012) 189:5503-7. doi:10.4049/jimmunol.1201413
45. Lee SJ, Dunmire S, Mc Sorley SJ.MHCclass-I-restrictedCD8Tcells play a protec-tive role during primary Salmonella infection. Immunol Lett (2012) 148:138-43. doi:10.1016/j.imlet.2012.10.009
46. Strugnell RA, Scott TA, Wang N, Yang C, Peres N, Bedoui S, et al. Salmonella vaccines: lessons from the mouse model or bad teaching? Curr Opin Microbiol (2014) 17:99-105. doi:10.1016/j.mib.2013.12.004
47. Simon R, Tennant SM, Galen JE, Levine MM. Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge. Vaccine (2011) 29:5094-106. doi:10.1016/j.vaccine.2011.05.022
48. Eisenstein TK, Angerman CR. Immunity to experimental Salmonella infection: studies on the protective capacity and immunogenicity of lipopolysaccharide, acetone-killed cells, and ribosome-rich extracts of Salmonella typhimurium in C3H/He J and CD-1 mice. J Immunol (1978) 121:1010-4.
49. Herzberg M, Nash P, Hino S. Degree of immunity induced by killed vaccines to experimental salmonellosis in mice. Infect Immun (1972) 5:83-90.
50. Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, et al. Sal-monella enterica serovar enteritidis core O polysaccharide conjugated to H:g,m fiagellin as a candidate vaccine for protection against invasive infection with S. enteritidis. Infect Immun (2011) 79:4240-9. doi:10.1128/IAI.05484-11